In an exclusive interview with BioPharm International at AAPS PharmSci 360, Sara Fathollahi, PhD, product application specialist, DFE Pharma, discusses one of the major challenges in the adoption of continuous manufacturing: variation in raw materials.
There is variation in raw materials, including both excipients and active pharmaceutical ingredients. Variations can include particle size, white density, etc., and these variations may impact the quality of the final product, Fathollahi states.
“This is very important to consider, and the manufacturers that want to enjoy the benefits of continuous manufacturing, such as faster production, more efficient production, and lower cost, [should] plan to overcome this challenge,” says Fathollahi.
